Drug
Tedizolid clinical trials
Includes 30 studies of Tedizolid phosphate.
- studies test it
- 35
- open now
- 2
- in phase 3
- 7
- first study started
- 2008
Keep track of what changes. Save the tedizolid studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2012 (5)
| Year | Studies |
|---|---|
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 20
- Phase 2
- 4
- Phase 3
- 7
- Phase 4
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 7
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (18) · Merck Sharp & Dohme LLC (5) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Bayer (2) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Tourcoing Hospital (1) · University of Southern California (1) · Dong-A ST Co., Ltd. (1)
Often tested with
Tested in the same studies.
Linezolid (2) · Tyramine (1) · Midazolam (1) · Rosuvastatin (1) · Cefaclor (1) · Ciprofloxacin (1) · Clindamycin (1) · Dicloxacillin (1)
Studies
Open first, then newest update. How each study uses tedizolid is read from its arms, and is right about nine times in ten.
Testing it · 35
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective EndocarditisRecruitingPhase 4Fundacion Clinic per a la Recerca BiomédicaNCT05398679Written as Tedizolid Oral Tablet
- Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)RecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT05534750Written as Tedizolid arm (SIVEXTRO®)
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT03176134Written as Tedizolid phosphate
- A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT03217565Written as IV Tedizolid Phosphate
- A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)CompletedPhase 1Merck Sharp & Dohme LLCNCT06733688Written as Tedizolid Phosphate Oral Formulation 1 (Reference)
- Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)CompletedPhase 2Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterNCT03009045Written as Tedizolid
- Tedizolid Prolonged Treatment for Prosthetic Joint InfectionsCompletedNot applicableTourcoing HospitalNCT03378427Written as Tedizolid Phosphate 200 MG [Sivextro]
- Pharmacokinetics of Tedizolid Phosphate in Cystic FibrosisCompletedPhase 4University of Southern CaliforniaNCT02444234Written as Tedizolid IV
- Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male VolunteersCompletedPhase 1Dong-A ST Co., Ltd.NCT02097043Written as DA-7218
- A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)CompletedPhase 1Merck Sharp & Dohme LLCNCT02750761Written as Tedizolid Phosphate (IV)
- Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure InfectionsCompletedPhase 2Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00761215Written as TR-701 200 mg
- Microdialysis and Pharmacokinetic Study of TR-701CompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00666601Written as TR-700 (active moiety)
- Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mgCompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01271998Written as TR-701 FA
- Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)CompletedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02276482Written as Tedizolid Phophate
- Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)CompletedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02019420Written as Tedizolid phosphate
- Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo MicrodialysisCompletedPhase 1Hartford HospitalNCT02620787Written as Tedizolid
- Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent PatientsCompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01156077Written as TR-701 FA
- A Thorough QT Study of TR-701free Acid (FA) in Healthy SubjectsCompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01461460Written as TR-701 FA 1200 mg
- Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) InfectionsCompletedPhase 3BayerNCT01967225Written as Tedizolid Phosphate (Sivextro, BAY1192631)
- TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedPhase 3Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01421511Written as TR-701 FA
Codes
What other systems call tedizolid · ClinicalTrials.gg INT005549
- MeSH (NLM) C546016tedizolidConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 97HLQ82NGLTEDIZOLIDConfirmed FDA, NLM, Wikidata
- RxNorm 1540825Confirmed FDA, Wikidata
- Wikidata Q7825683tedizolidConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84222TedizolidOne source FDA
- DrugBank DB14569One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546016 | tedizolid | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 97HLQ82NGL | TEDIZOLID | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1540825 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7825683 | tedizolid | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84222 | Tedizolid | One source FDA |
| DrugBank | DB14569 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.